Longitudinal analysis of COVID-19 patients shows age-associated T cell changes independent
 of ongoing ill-health

3	Liam T	ownsend <sup>1,2</sup> , Adam H Dyer <sup>3</sup> , Aifric Naughton <sup>4</sup> , Rachel Kiersey <sup>4</sup> , Dean Holden <sup>4</sup> , Mary
4	Gardin	er <sup>4</sup> , Joanne Dowds <sup>5</sup> , Kate O'Brien <sup>5</sup> , Ciaran Bannan <sup>1</sup> , Parthiban Nadarajan <sup>6</sup> , Jean Dunne <sup>4</sup> ,
5	Ignacic	Martin-Loeches <sup>7</sup> , Padraic G Fallon <sup>8</sup> , Colm Bergin <sup>1,2</sup> , Cliona O'Farrelly <sup>9,10</sup> , Cliona Ni
6	Chealla	aigh <sup>1,2</sup> , Nollaig M Bourke <sup>3</sup> , Niall Conlon <sup>4,11</sup>
7	1.	Department of Infectious Diseases, St James's Hospital, Dublin, Ireland
8	2.	Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine
9		Institute, Trinity College Dublin, Ireland
10	3.	Department of Medical Gerontology, School of Medicine, Trinity Translational Medicine
11		Institute, Trinity College Dublin, Ireland
12	4.	Department of Immunology, St James's Hospital, Dublin, Ireland
13	5.	Department of Physiotherapy, St James's Hospital, Dublin, Ireland
14	6.	Department of Respiratory Medicine, St James's Hospital, Dublin, Ireland
15	7.	Department of Intensive Care Medicine, St James's Hospital, Dublin, Ireland
16	8.	School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin,
17		Ireland
18	9.	School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity
19		College Dublin, Ireland
20	10.	Department of Comparative Immunology, School of Medicine, Trinity College Dublin,
21		Ireland

11. Department of Immunology, School of Medicine, Trinity College Dublin, Ireland

# 23 Corresponding Author

- 24 Liam Townsend
- 25 Department of Infectious Diseases, St James's Hospital, Dublin, Ireland
- 26 <u>townsenl@tcd.ie</u>
- 27 +353 14083709
- 28 ORCID 0000-0002-7089-0665
- 29



#### 32 Abstract

The trajectory of immunological and inflammatory changes following acute COVID-19 infection are unclear. We investigate immunological changes in convalescent COVID-19 and interrogate their potential relationships with persistent symptoms, termed *long COVID*.

We performed paired immunophenotyping at initial SARS-CoV-2 infection and convalescence (n=40, median 68 days) and validated findings in 71 further patients at median 101 days convalescence. Results were compared to 40 pre-pandemic controls. Fatigue and exercise tolerance were assessed and investigated their relationship with convalescent results.

We demonstrate persistent expansion of intermediate monocytes, effector CD8+, activated CD4+ and CD8+ T cells, and reduced naïve CD4+ and CD8+ T cells at 68 days, with activated CD8+ T cells remaining increased at 101 days. Patients >60 years also demonstrate reduced naïve CD4+ and CD8+ T cells and expanded activated CD4+ T cells at 101 days. Ill-health, fatigue, and reduced exercise tolerance were common but were not associated with immunological changes.

#### 46 Introduction

COVID-19, caused by the SARS-CoV-2 virus, is responsible for the largest global pandemic in 47 48 modern medicine (1). The features of acute illness are well-described, ranging from disturbance in smell and mild coryzal symptoms to acute respiratory failure and the need for invasive 49 mechanical ventilation (2, 3). Age is strongly associated with disease severity, with older 50 individuals suffering poorer outcomes (4, 5). The immunological changes associated with severe 51 52 disease are also known, with increased inflammatory proteins, coagulopathy and changes in 53 myeloid cell populations reported (6, 7). In particular, severe COVID-19 is characterised by 54 expansion of immature myeloid populations, with loss of HLA-DR expression by monocytes and 55 loss of CD10 expression on neutrophils (8, 9). Panlymphopenia is also prominent, with CD4+ T 56 cells particularly affected (10, 11).

In contrast to the well-characterised inflammatory and immunological signature of acute disease, 57 58 relatively little is known about resolution of inflammatory markers and immune cell population changes during the convalescent period. These gaps in current knowledge of convalescence are 59 60 of immediate importance, with the emergence of prolonged symptoms following resolution of acute infection, termed long COVID (12). The immunological features of this syndrome are only 61 62 being described at present, with short-term follow up (less than one month) of non-hospitalised patients showing expansion of activated CD4+ and CD8+ T lymphocytes (13). Despite the 63 importance of this issue towards understanding the long-term consequences of COVID-19, 64 65 further insight into how long such changes persist, and the contribution of immune responses to the symptoms of *long COVID*, is lacking. 66

The clinical characteristics of long COVID are protean and an agreed definition has yet to be found; the most common symptoms include fatigue, shortness of breath and reduced exercise tolerance (14, 15). The possible mechanisms for post-COVID fatigue and breathlessness have been speculated to be associated with deconditioning, as well as hypothesised to be due to persistent inflammation or immune activation (16). However, these connections remain unexplored.

We hypothesised that, given the strong association between the immune response and severity of acute COVID-19 infection, there may be persistent and chronic changes to the immune system which may be linked to the long-term effects of COVID-19. Our goal was to determine if persistent inflammatory and immune cell dysregulation was evident in the aftermath of SARS-CoV-2 infection. We further investigated the factors that might be associated with potential persistent immune dysregulation and to interrogate the relationship between these measures and physical ill-health post-COVID-19.

#### 81 Results

#### 82 *Participant characteristics*

83 Clinic appointments were offered to 356 patients, of whom 111 (31%) attended (Supplemental 84 Figure 1). We recruited three cohorts for this study. Cohort one comprised of forty participants 85 (aged 51.4  $\pm$  16.9 years, 52.5% female) recruited for matched longitudinal blood sampling and immunophenotyping at (i) time of initial COVID-19 disease and (ii) ten-week follow-up (median: 86 68, 61-72 days). Of these, 8 had mild (not hospitalised), 24 moderate (hospitalised) and 8 severe 87 88 (required admission to Intensive Care Unit) acute COVID-19 disease. Cohort two comprised of 71 individuals (aged 44.3 ± 14.1 years; 70% female) recruited from the post-COVID clinic at fourteen 89 90 weeks (median: 101, 76-117 days) after initial COVID-19 illness. Cohort two was younger, had lower levels of frailty and had a greater proportion of females in comparison to cohort one. 91 Cohort two was also predominantly healthcare workers. In cohort two, 47 had mild, 18 had 92 moderate, and 6 had severe acute COVID. All patients had lymphoid and myeloid 93 94 immunophenotyping and detailed clinical and health assessments performed at outpatient appointment. The combined sample consists of both cohort one and cohort two. Detailed 95 96 characteristics of cohort one, cohort two and the combined samples are presented in Table 1.

97

## 98 Table 1: Cohort characteristics

Characteristic	All (n = 111)	Cohort One (n = 40)	Cohort Two (N = 71)	Statistic
	()			
Sex, female, n (%)	70 (63.06)	21 (52.5)	49 (70)	$\chi^2 = 8.3, p = 0.004$
Mean age (SD)	45.9 (14.9)	51.4 (16.9)	44.3 (14.1)	t = 2.2, p = 0.01
Clinical Frailty Score, median (IQR)	1 (1 – 2)	2 (1 – 2.5)	1 (1-2)	z = -4.3, p <0.001
Co-morbidities, median, n (IQR)	1 (0 – 2)	1 (0 – 2)	0 (0-2)	z = -1.11, p = 0.27
Co-medications, median, n (IQR)	1 (0 – 3)	1 (0 – 4)	1 (0-2)	z = -1.14, p = 0.25
Admission during acute infection, n (%)	48 (43)	30 (75)	18 (25)	χ <sup>2</sup> = 25.7, p <0.001
Admission to ICU, n (%)	14 (12.6)	8 (20)	6 (8)	$\chi^2 = 3.1, p = 0.08$
Time to follow up, days, median (IQR)	82 (67 – 112)	68 (60.5 – 71)	101 (76-117)	z = 5.04, p <0.001
Feel back to full health (yes), n (%)	37 (33)	22 (55)	15 (21.2)	χ <sup>2</sup> = 16.7, p <0.001
Healthcare worker, n (%)	74 (66.7)	15 (37.5)	59 (83)	χ <sup>2</sup> = 23.9, p <0.001
Distance at 6MWT, m, median (IQR)	475 (415 – 540)	435 (390 – 540)	480 (430-540)	z = 4.5, p = 0.65
MBS, median (IQR)	3 (2 – 5)	3 (2 – 5)	3 (2 - 5)	z = -0.42, p = 0.68
Fatigue score, median (IQR)	15 (11 – 20)	13 (11 – 18)	17 (12 - 21)	z = 1.58, p = 0.11
Fatigue <i>caseness</i> , n (%)	61 (55)	15 (37.5)	46 (65)	χ <sup>2</sup> = 7.7, p 0.01

99

100 χ2, Chi-squared test; t, t-test; z, Wilcoxon rank-sum test.6MWT, 6-minute-walk test; MBS, Modified Borg Dyspnoea Scale

101 Cohort three comprised of forty healthy pre-pandemic controls (aged 47.3 ± 15.3 years; 55% 102 female) and was used for comparison of extended T cell immunophenotyping parameters, with 103 20 of these also having myeloid immunophenotyping performed. There were no age/sex 104 differences between controls and cohort one (t = 0.9, p = 0.35;  $\chi^2$  = 2.5, p = 0.11 respectively) or 105 cohort two (t = 1.1, p = 0.27;  $\chi^2$  = 0.05, p = 0.82 respectively).

#### 106 Persistent ill-health evident at 82 days following COVID-19

We first investigated the prevalence of the cardinal features of long COVID in our cohort. All 107 participants were assessed for ongoing ill-health, fatigue and exercise tolerance at time of 108 109 convalescent immunophenotyping (median 82 days, IQR 67 – 112). Most patients (71/111, 64%) reported that they did not feel back to full health, while 61 (55%) met the case definition for 110 111 fatigue. The median fatigue score for the cohort as a whole was 15 (IQR 11 - 20), while the median fatigue score of those who met the case definition for fatigue was 20 (IQR 17 - 23) (Table 112 113 1). Two-thirds of participants (76/111; 68.4%) underwent a six-minute-walk test (6MWT). The median distance covered was 475m (IQR 415 – 540). The median maximal Modified Borg 114 Dyspnoea Scale (MBS) score reported was 3 (IQR 2 - 5). The median distance covered by 115 convalescent individuals was lower than that seen in healthy populations, but higher than that 116 reported in post-ARDS patients (17, 18). These findings demonstrate that the primary features of 117 long COVID are common in our convalescent cohort who attended for follow up appointment. 118 We therefore wanted to further investigate if there were further physiological changes, 119 120 particularly in relation to immunity, in COVID convalescence.

121 Recovery from COVID-19 is associated with resolution of inflammation, coagulopathy, and cell 122 turnover

123 We examined the levels of inflammatory, cell turnover and coagulation markers, all of which are 124 known to be profoundly disturbed during acute COVID-19. Individuals in cohort one with acute COVID-19 had coagulopathy (with increased D-Dimer and fibrinogen), a marked pro-125 inflammatory response (elevated CRP, IL-6, TNF- $\alpha$ , IL-8 and IL-1 $\beta$ ) and lymphopenia, with an 126 127 increase in the neutrophil: lymphocyte ratio. All of these parameters had significantly improved 128 by ten weeks (Table 2 and Figure 1) in the majority of individuals. Several participants had 129 persistent lymphopenia (5/40, 12.5%) and elevated D-dimer levels (10/40; 25%) at 10 weeks post infection. 130

## 132 Table 2. Active COVID-19 is associated with a significant pro-inflammatory response which normalises following resolution of

## 133 acute infection

Laboratory Parameter	Reference Range	Values		Statistic	N (%) Abnormal Results	
		Acute COVID-19	Post COVID-19		Acute COVID-19	Post COVID- 19
Routine Laboratory Markers						
Neutrophil Count (x10 <sup>9</sup> /L)	2-7.5	3.5 (2.3-4.4)	3.15 (2.55-4.05)	z =0.47, p =0.64	5 (13%)	0 (0%)
Lymphocyte Count (x10 <sup>9</sup> /L)	1.5-3.5	1.3 (1-1.8)	1.9 (1.55-2.35)	z=-2.85, p = 0.004	24 (60%)	5 (13%)
Neutrophil: Lymphocyte ratio		2.5 (1.3-3.9)	1.7 (1.3-2.1)	z =2.82, p = 0.005		
Lactate Dehydrogenase (U/L)	135-250	230 (190-308)	187.5 (165-210)	z = 3.27, p = 0.001	14 (35%)	0 (0%)
Fibrinogen (g/L)	1.9-3.5	4.4 (3.6-6)	3 (2.6-3.4)	z = 2.86, p = 0.004	22 (55%)	2 (5%)
D-Dimer (ng/mL)	0-500	496 (258-851)	396 (215-599)	z = 1.93, p = 0.05	20 (50%)	10 (25%)
C Reactive Protein (mg/L)	0-5	28.15 (3.16-53.58)	1.43 (1.00-1.99)	z = 4.75, p<0.001	31 (78%)	3 (8%)
Pro-Inflammatory Cytokines						
IL-6 (pg/mL)		15.3 (4.19-31.7)	2.17 (1.45-3.35)	z = 4.72, p<0.001	22 (55%)	3 (8%)
IL-1β (pg/mL)		0.26 (0.18-0.45)	0.19 (0.11-0.31)	z = 2,1, p = 0.035	1 (2.5%)	1 (2.5%)
TNFα (pg/mL)		21.3 (16-25)	12.2 (10.3-14.8)	z = 3.95, p<0.001	16 (40%)	2 (5%)
IL-8 (pg/mL)		31.1 (20.3-46.4)	16.5 (12.3-21.4)	z = 4.23, p<0.001	17 (42.5%)	4 (10%)
Soluble CD25 (pg/mL)		1,898 (1520-2455)	1,187 (878-1634)	z = 4.61, p<0.001	11 (28%)	2 (5%)

134

135 Data presented as medians with IQRs. z, Wilcoxon matched pair



- 139 **Figure 1: (A)** Coagulopathy (fibrinogen, D-dimer) **(B)** Inflammatory (CRP, IL-6, sCD25, IL-1β, IL-8,
- 140 TNFα, LDH) (C) Cell turnover (lymphocytes, neutrophil: lymphocyte ratio, neutrophils). Shaded
- 141 areas show normal ranges for each measure. Differences assessed by Wilcoxon signed-rank
- 142 test. \* p <0.05, \*\* p <0.01, \*\*\*p<0.001, ns = Not Significant

143 Persistent expansion of intermediate monocytes at 10 weeks post infection

144 We found that acute COVD-19 was associated with expansion in immature neutrophils and 145 reduced overall CD10-expressing neutrophils (Figures 2A, 2B). These changes in neutrophils had 146 resolved by ten weeks to a level comparable to that of healthy controls. While HLA-DR+ 147 monocytes increased at convalescence to levels of healthy controls, this increase was not statistically significant; this likely reflects the mixed severities of the populations (Figure 2C). We 148 also noted a significant expansion in the proportion of CD14+CD16+ intermediate monocytes in 149 150 acute infection, with levels remaining significantly elevated at convalescence in comparison to 151 controls (Figure 2E). Changes in the proportion of other monocyte subsets resolved to a level comparable to control participants (Figures 2D, 2F). We found no association between 152 convalescent intermediate monocytes and severity of initial infection ( $\chi^2$ =0.58, p=0.76). 153





Figure 2: Matched peripheral whole blood myeloid cell proportions from n=40 patients recovered
 from COVID-19 versus uninfected controls (n=20). (A) CD10-CD16- immature neutrophils (B)
 CD10+ neutrophils (C) HLA-DR+ monocytes (D) non-classical monocytes (E) intermediate
 monocytes (F) classical monocytes. Differences assessed using Wilcoxon rank-sum (unpaired)
 and Wilcoxon sign-rank (paired) tests. \* p <0.05, \*\* p <0.01, \*\*\*p<0.001, NS = Not Significant</li>

#### 162 Persistent changes to T cells in COVID-19 convalescence

A hallmark of acute COVID-19 is profound lymphopenia, so we sought to investigate T cell phenotypes in our longitudinal acute-convalescent cohort. As expected, acute SARS-CoV-2 infection was associated with striking lymphopenia (**Figure 3B**). We found a significant reduction in the total number of immune (CD45+) cells, total lymphocytes (CD3+), CD4+ T cells and CD8+ T cells in comparison to healthy controls (n=40). Despite this significant lymphopenia during acute COVID-19 infection, at ten weeks post-COVID all of these counts had significantly recovered and were similar to those of control participants (**Figures 3A-3D**).

170 On more detailed T cell immunophenotyping, we found that acute infection was associated with a significant reduction in absolute naïve CD4+ and CD8+ T cell counts and increased activated 171 172 CD4+ and CD8+ T cell numbers in comparison to controls. Over the course of ten weeks, whilst naïve CD4+ and CD8+ cell counts had partially recovered, they remained significantly lower than 173 174 the levels of healthy controls (Figures 3E, 3F). Numbers of effector CD8+ T cells remained expanded over the course of COVID-19 recovery and counts were significantly greater than 175 healthy controls at ten-week follow-up (Figure 3G). One of the most notable differences was that 176 activated T cell numbers did not significantly change with resolution of illness; there were 177 178 significantly higher numbers of activated CD4+ and CD8+ T cells in patients ten weeks post-COVID 179 compared to healthy controls (Figures 3H, 3I). Interestingly, there was no association between convalescent lymphocyte subset counts and severity of initial infection (naïve CD4+ T cells 180  $\chi^2$ =0.31, p=0.86, naïve CD8+ T cells  $\chi^2$ =4.12, p=0.13, effector CD8+ T cells  $\chi^2$ =0.29, p=0.19, 181 182 activated CD4+ T cells  $\chi^2$ =0.28, p=0.87, activated CD8+ T cells  $\chi^2$ =0.29, p=0.07).



## 183 Figure 3: Lymphocyte subsets from acute to convalescent COVID-19.

Figure 3: Matched peripheral whole blood lymphoid cell counts from n=40 patients recovered
from COVID-19 versus uninfected controls (n=40). (A) CD45+ immune cells (B) CD3+ lymphocytes
(C) CD4+ T cells (D) CD8+ T cells (E) naïve CD4+ T cells (F) naïve CD8+ T cells (G) effector CD8+ T
cells (H) activated CD4+ T cells (I) activated CD8+ T cells. Differences assessed using Wilcoxon
rank-sum (unpaired) and Wilcoxon sign-rank (paired) tests. \* p <0.05, \*\* p <0.01, \*\*\*p<0.001, ns</li>
Not Significant

Alterations in the B cell compartment were relatively minor, with B cell counts recovering entirely 193 194 at convalescence (Supplemental Figure 2A). Similarly, while acute COVID-19 was also associated with a significant decrease in NK cells, these had resolved to levels of healthy controls by ten 195 196 weeks after acute infection (Supplemental Figure 2B). Collectively, longitudinal follow up of 197 cohort one during convalescence revealed that while the overall panlymphopenia resolved, 198 infected individuals maintained aberrations in certain lymphocyte subset compartments; 199 specifically, persistently reduced naïve CD4+ and CD8+ T cells, in addition to expanded effector 200 CD8+ T cells and activated CD4+ and CD8+ T cells at a median of 68 days following infection.

201 Given the persistent T-cell subset changes seen in cohort one, as well as the expansion in 202 intermediate monocytes, we sought to validate these changes in a larger cohort of convalescent 203 individuals with blood samples obtained at a longer follow time of 101 days (cohort two). The 204 observations in cohort one were confirmed, with no differences in numbers of total immune 205 (CD45+) cells, total lymphocytes (CD3+), CD4+ T cells or CD8+ T cells at 14 weeks in comparison 206 to controls (Supplemental Figure 3). In contrast to the paired analysis at 10 weeks following acute infection, we observed no significant differences in naïve CD4+ or CD8+ cells, suggesting these 207 208 cells had resolved to normal levels by 14 weeks in convalescence (Figure 4). However, the increased numbers and proportions of activated CD8+ T cells in post-COVID samples persisted, 209 210 even at this longer time point of follow up in comparison to cohort one (median 101 days versus 211 68 days) (Figure 4). There were no changes in activated CD4+ T cells seen, while convalescent COVID patients had an increased proportion of effector CD8+ T cells. The significant differences 212 213 in proportion of intermediate monocytes were not seen in this cohort, with all monocyte 214 populations returning to levels similar to controls (Supplemental Figure 4).

### 215 Figure 4: Lymphocyte subsets in convalescent COVID-19



- 216
- **Figure 4:** Convalescent lymphocyte subsets from n=71 patients recovered from COVID-19
- versus n=40 uninfected controls. (A) CD4+ T cells, showing proportion and absolute number of
- 219 naïve and activated CD4+ T cells (B) CD8+ T cells, showing proportion and absolute number of
- 220 naïve, activated and effector CD8+ T cells, Wilcoxon rank-sum test used to assess differences. \*
- 221 p <0.05, \*\* p <0.01, \*\*\*p<0.001, ns = Not Significant

Interestingly, further interrogation of these convalescent T cell results revealed that there was a relationship between these T cell changes and the persistent elevation in D-Dimer levels that we noted in our earlier analysis. Twenty patients (20/111, 18%) had an elevated D-dimer at time of assessment. D-dimer levels were negatively associated with the proportion of naive CD8+ T cells (**Figure 5A**), while they were positively associated with activated CD4+ T cells (**Figure 5B**) and activated CD8+ T cells (**Figure 5C**). However, there was no relationship between D-dimer levels and naïve CD4+ T cells ( $r^2$ =-0.15, p=0.13) or effector CD8+ T cells ( $r^2$ =0.12, p=0.24).



231

Figure 5: Correlation between D-dimers and (A) naïve CD8+ T cells, (B) activated CD4+ T cells and
 (C) activated CD8+ lymphocytes. D-dimer shown as log scale. Dashed vertical line represents

lower limit of detection for D-dimer assay. Correlation assessed by Pearson's chi-squared test.

236 Older patients have worse outcomes in acute SARS-CoV-2 infection, but little is known regarding 237 recovery of their immune system following infection. As we had noted interesting lymphocyte 238 abnormalities post-COVID, we further investigated if age influences any of the dynamic changes T cell responses seen in convalescence. We stratified our convalescent patients into 20-year age 239 brackets: 20 – 39 (n=43), 40 – 59 (n=49) and 60 – 80 (n=19). There was no difference in time to 240 follow up between the three age groups (z=1.5, p=0.47). The older 60 – 80 cohort were more 241 242 likely to have been admitted during acute infection than the youngest (z=4.62, p=<0.001) and 40 243 -59 (z=2.77, p=0.02) cohorts. We also stratified our healthy cohort into identical age brackets: 244 20 – 39 (n=16), 40 – 59 (n=10), and 60 – 80 (n=14). There were distinct age-associated changes 245 seen in lymphoid populations in the convalescent cohort, with an age-associated decline in both absolute number and proportions of naïve CD4+ and CD8+ cells and an age-associated increase 246 247 in activated CD4+ and CD8+ cells (Supplemental Figure 5). There were minor increases in effector 248 CD8+ T cells with age (Supplemental Figure 5). We also investigated disease-associated effects by comparing these results to age-matched controls. There were distinct differences noted, with 249 the most dramatic being in the oldest cohort, with post-COVID individuals having reduced 250 251 number of naïve CD4+ and naïve CD8+ (Figures 6A, 6C) and increased number and proportion of 252 activated CD4+ and CD8+ cells (Figures 6B, 6E) compared to age-matched controls. There were 253 no differences between the age-matched controls and infected individuals in the youngest cohort. The 40 – 59 age group showed increased number of effector CD8+ T cells (Figure 6C), 254 255 activated CD4+ and activated CD8+ T cells in comparison to uninfected controls, with no 256 differences in naïve T cell counts. These changes were mirrored in the proportion of T cell

- populations across age groups (Supplemental Figure 6). These data suggest that in those >60
- 258 years of age the post-COVID changes in T cells persist longer than in younger individuals.

- 260 Figure 6: Age-associated changes in convalescent lymphocyte subsets versus age-matched
- 261 controls.



- Figure 6: Lymphocyte immunophenotyping of convalescent COVID patients (n=111) broken down
   by age with age-matched controls, showing absolute number of (A) naïve CD4+ T cells and (B)
   activated CD4+ T cells, and (C) naïve CD8+ T cells, (D) activated CD8+ T cells and (E) effector CD8+
   T cells. Differences assessed by Wilcoxon rank-sum test. \* p <0.05, \*\* p <0.01, \*\*\*p<0.001, ns =</li>
- 267 Not Significant

268 Persistent symptoms are independent of T cell immunophenotype following COVID-19 illness

269 We have demonstrated the high prevalence of ill-health and the cardinal features of long COVID 270 in our cohort Our analysis has also revealed persistent changes to T cells, most notably activated 271 CD8+ T cells, in the convalescent period following COVID-19. We finally wanted to investigate the 272 relationship between immunophenotyping parameters and subjective symptoms of fatigue, as assessed by CFQ-11 score, and exercise tolerance, as assessed by performance on the 6MWT. 273 We used linear regression under unadjusted conditions and controlled for age, sex and clinical 274 275 frailty score in order to determine relationships. There were no associations between naïve CD4+, 276 naïve CD8+, effector CD8+, activated CD4+, or activated CD8+ T cells and fatigue score, distance 277 reached on the 6MWT or maximal MBS reported under any of the conditions examined (Table 3, 278 Figure 7). We also evaluated the association between physical health measures and classical, 279 intermediate and non-classical monocyte populations, given the intermediate monocyte 280 differences we saw at 68 days. There were no associations with monocyte populations (Supplemental Figure 7). 281

## Table 3: No relationship between extended T cell subsets and symptoms of fatigue, dyspnoea or distance walked on the sixminute walk test post-COVID-19.

	CFQ-11				6MWT (meters)				Borg Dyspnoea Scale			
	Model 1		Model 2 (adj.)		Model 1		Model 2 (adj.)		Model 1		Model 2 (adj.)	
	β Coeff (95% Cl)	Р	Adj. β Coeff (95% Cl)	р	β Coeff (95% Cl)	р	Adj. β Coeff (95% Cl)	р	β Coeff (95% Cl)	р	Adj. β Coeff (95% Cl)	р
Naïve CD4 Count	0.005 (0.00, 0.01)	0.046	0.004 (-0.001, 0.01)	0.07	-0.05 (-0.19, 0.09)	0.50	-0.14 (-0.26, -0.02)	0.02	-0.0002 (-0.003, 0.002)	0.83	-0.0002 (-0.003, 0.002)	0.89
Naïve CD8 Count	0.01 (0.001, 0.02)	0.04	0.01 (0.001, 0.02)	0.04	0.20 (-0.03, 0.42)	0.08	-0.10 (-0.34, 0.13)	0.39	0.001 (-0.003, 0.005)	0.70	0.003 (-0.002, 0.008)	0.21
Effector CD8 Count	-0.002 (-0.01, 0.01)	0.63	0.003 (-0.05, 0.05)	0.92	-0.04 (-0.20, 0.12)	0.65	0.01 (-0.13, 0.15)	0.85	-0.002 (-0.005, 0.001)	0.22	-0.002 (-0.004, 0.001)	0.23
Activated CD4 Count	0.04 (-0.69, 0.77)	0.82	-0.01 (-0.06, 0.04)	0.75	-1.04 (-2.31, 0.23)	0.11	-0.0002 (-1.19, 1.19)	0.99	-0.0001 (-0.02, 0.02)	0.99	-0.01 (-0.03, 0.02)	0.48
Activated CD8 Count	-0.01 (-0.02, 0.01)	0.32	-0.01 (-0.02, 0.004)	0.20	-0.08 (-0.35, 0.19)	0.56	0.09 (-0.16, 0.33)	0.48	-0.003 (-0.008, 0.002)	0.23	-0.004 (-0.01, 0.001)	0.10

Linear regression. CI; confidence interval. Model 1, unadjusted; Model 2, adjusted for age, sex, Clinical Frailty Scale and severity of

287 acute COVID-19 illness. Bonferroni correction, statistical significance p <0.01



290

Figure 7: Relationship with fatigue, perceived exertion and 6MWT distance with (A) naïve CD4+ T cells, (B) naïve CD8+ T cells, (C) effector CD8+ T cells, (D) activated CD4+ T cells and (E) activated CD8+ T cells. Relationships assessed using linear regression. CFQ-11 = Chalder Fatigue Questionnaire-11

- 296 These findings suggest that persistent ill-health and fatigue are frequently reported at a medium-
- term interval following COVID-19, but they are independent of any persistent changes to the
- 298 immune parameters investigated in this study.

300 Discussion

We show evidence of persistent abnormalities of T cell responses in the aftermath of acute SARS-301 CoV-2 infection that are unrelated to initial disease severity across the spectrum of disease, with 302 severity ranging from mild disease managed in the community to requirement for ICU care. 303 304 Specifically, we demonstrate an expansion of effector CD8+ T cells, activated CD4+ and CD8+ T cell populations and reduction in naïve CD4+ and CD8+ T cells at ten weeks following acute 305 infection. Further analysis of COVID convalescence found that the expansion of activated CD8+ T 306 307 lymphocytes is still evident at a median of 101 days following infection. Equally notable is the recovery post-COVID of myeloid populations to levels similar to healthy controls. While we report 308 persistent expansion of intermediate monocytes at 68 days, all monocyte populations have 309 310 normalized at 101 days. Given that the myeloid compartment is significantly altered in acute 311 infection, it is reassuring to see resolution of these changes at convalescence. Similarly, routine 312 clinical measures of inflammation and coagulation also return to normal levels. The exception to this is D-dimers, which remain elevated in 18% of patients. Persistent ill-health is common in our 313 314 cohort, with almost two-thirds (64%) not feeling back to full health, and fatigue seen in more 315 than half the cohort. These are the cardinal features described in *long COVID*. However, these 316 findings of persistent ill-health are independent of immunological parameters measured.

While persistent expansion of activated T lymphocytes are described in the setting of chronic viral infection, they are less commonly seen following infection by an acute pathogen (19). However, persistent activation of CD8+ T cells has been reported in the setting of parvovirus B19 infection, as well as the aftermath of severe influenza A H7N9 infection (20, 21). Interestingly, we demonstrate that D-dimer levels are closely associated with both activated CD4 and CD8

lymphocyte counts. This persistent elevation of D-dimers mirrors early reports from elsewhere 322 323 (22). We now report that the elevations in D-dimers is associated with increased levels of activated T lymphocytes and reduced levels of naïve T lymphocytes. Potential mechanisms for 324 325 this include persistent endothelial dysfunction following resolution of infection, as well as the 326 degradation of extra-vascular sites of coagulation (23, 24). D-dimers have also been shown to be 327 markers of crosstalk between the coagulation system and adaptive immune system in chronic viral infection such as HIV (25). The data we present here highlight the need for further 328 329 investigations of such crosstalk in the context of COVID-19.

330 One of the most striking findings was that these T cell-specific changes are most marked in older 331 >60-year-old participants, with persistent abnormalities across naïve and activated CD4+ and 332 CD8+ T cells, while those aged <40 show complete resolution of these changes. While age is 333 known to affect immune recovery in treated chronic infections such as HIV, there is relatively 334 little known about ageing and immune recovery following acute viral infections (26). The ageing 335 immune system has been implicated in the ageing-associated mortality rate in acute COVID-19 336 (27). T cell responses are crucial in modulating the immune response and preventing host damage in acute viral infections such as influenza (28). Impairment of the adaptive immune system with 337 age, in particular immunosenescence, has been well-described (29). This is of particular 338 339 importance when considering the impact of lasting immunity in previously infected older 340 individuals and how little is known about adaptive immune responses in this population in the context of COVID-19. The ability to sustain an effective memory immune response to infection 341 342 has been shown to diminish with age (30). A recent study found there was a general decline in 343 recognition of viral-associated peptides between the ages of 42 and 58 in a pre-pandemic cohort

(31). Another important consideration regarding our results is how such alterations may impact
on the potential long-term efficacy of vaccination of older cohorts, where responses have
previously been shown to be highly variable (32, 33). These results emphasize the importance of
further study into activation and resolution of immune responses in SARS-CoV-2 infection in older
individuals.

Interestingly, we found the cardinal features of long COVID, namely the presence of fatigue and 349 reduced exercise tolerance, had no association with lymphocyte subset changes. Nonetheless, 350 351 we demonstrate a large burden of fatigue, breathlessness, and ill-health in this cohort. This is 352 reflective of previous clinical descriptors of long COIVD cohorts. Our group have previously 353 reported a high prevalence of post-COVID fatigue, which was independent of severity of initial 354 infection (34). These findings have been replicated in subsequent studies showing persistent illhealth in young, otherwise healthy individuals (35). Our findings further highlight the difficulty in 355 356 establishing a reliable biomarker for ongoing ill-health following COVID-19 infection.

357 While it is likely that the proportion of those reporting persistent ill-health is likely confounded by their increased likelihood to attend for follow-up, it demonstrates a significant burden of 358 359 morbidity. It will be illuminating to follow the prevalence of autoimmune disease in the general population in the post-pandemic era. This is particularly relevant given the concept of bystander 360 361 T cell activation during viral infection. Bystander T cell recruitment has been described in both hepatitis A and influenza A infection (36, 37). While the activation of such T cells are considered 362 363 beneficial in the control of acute infection and protective immunity, such non-specific immune activation has been associated with immunopathology, or host damage (38). Indeed, activation 364 of both CD4+ and CD8+ lymphocytes in acute infection has been associated with the 365

development of a wide array of autoimmune conditions (39, 40). The potential for SARS-CoV-2 366 367 to cause immunopathology has been proposed as a mechanism behind multisystem inflammatory syndrome in children (MIS-C), a new paediatric inflammatory condition associated 368 369 with COVID-19 (41). Autoantibodies against multiple cell types have been demonstrated in this 370 condition, while immune complex formation has also been implicated (42, 43). Furthermore, this 371 is similar to the immunopathology seen in other post-infectious autoimmune conditions, such as Kawasaki disease (44). Pro-thrombotic autoantibody generation has also been described in acute 372 373 COVID-19 in adult populations, which would link both activated T lymphocytes and elevated D-374 dimers (45). D-dimer levels have also been reported to correlate with CD8+ lymphocytes in MIS-C (46). Further characterisation of these persistently activated cells is warranted to inform 375 376 assessment of their functional consequences.

Our study has several limitations worth noting. It is a single-centre study at a single medium-term interval. However, we have two separate convalescent time points, in addition to data from acute illness. This allows a disease and recovery trajectory to be plotted. We have loss to follow-up, with 31% of patients attending their outpatient appointments. This is a common challenge seen in research conducted in clinical ambulatory care settings. However, our cohort may have an increased burden of symptoms following COVID-19 than that seen in the entire affected population.

The results reported here provide insights into the immune consequences of SARS-CoV-2 infection, as well as the age effects on immune recovery. It provides possible mechanisms for immunopathology and should inform the design of ongoing studies into the immunological consequences of COVID-19 and associations with long COVID clinical features.

In conclusion, we report several key findings that add significant knowledge regarding resolution 388 389 of the immunological responses in the convalescent period of COVID-19 infection. Encouragingly, 390 our matched longitudinal patient data shows that all cell counts return towards levels of healthy controls. Although there are persistent lymphocyte and monocyte abnormalities at 68 days, 391 392 these had resolved by 101 days post infection with the exception of a persistent expansion of 393 activated CD8+ T cells. We show that age, while being strongly associated with poor outcome in 394 acute COVID, is also strongly associated with impaired immunological recovery in convalescence. 395 The association of D-dimer levels with activated lymphocytes provide a potential basis for persistent immune dysfunction following SARS-CoV-2 infection. While we demonstrate the 396 burden of persistent ill-health following SARS-CoV-2 infection, this was not associated with 397 immunological changes. 398

#### 400 Methods

#### 401 *Study setting and participants*

402 This study was carried out in the post-COVID-19 clinic at St James's Hospital, Dublin, Ireland. 403 Appointments were offered to all individuals with a positive SARS-CoV-2 nasopharyngeal swab 404 PCR at our institution between March and May 2020, including both those hospitalised and those 405 managed in the community during their acute illness. Severity of initial infection was graded as mild (did not require hospitalisation), moderate (required hospitalisation) or severe (required 406 407 intensive care unit admission). Appointments were offered at a minimum of six weeks following 408 resolution of symptoms or hospital discharge. Outpatient appointments were not offered to 409 residents in long term care facilities.

#### 410 Inflammatory makers and immunophenotyping

Blood sampling was incorporated as part of routine phlebotomy occurring on the same day as 411 412 study participation. An identical sampling and analytic pipeline was implemented on the cohort 413 during acute infection. IL-6, IL-8, IL-1 $\beta$ , TNF- $\alpha$  and soluble CD25 levels were measured in serum 414 by ELISA (Ella ProteinSimple). Immunophenotyping by flow cytometry was carried out on fresh 415 whole EDTA-treated blood and samples were analysed on a FACS Canto II Flow Cytometer (BD 416 San Jose USA), using BD DIVA v8 and FLO Jo v10 software. BD FACSCanto<sup>™</sup> clinical software was used for acquisition of BD Multitest<sup>™</sup> 6-colour TBNK and TruCount tubes. All other 417 immunophenotyping samples were analysed using BD DIVA v8 and FLO Jo v10 software 418 (Supplemental Figure 8). The frequency and absolute cell counts of CD45+ T cells (CD3+, CD4+ 419 and CD8+), B cells (CD19+) and NK cells (CD16+CD56+) were generated by BD Multitest<sup>™</sup> 6-colour 420

TBNK and TruCount method. Naive (CD27+) and effector (CD27-) CD4+ or CD8+ T cells were 421 422 characterised for expression of CD27, CD45RA and CD197. T cell activation was assessed by CD38 and HLA-DR expression. Absolute cell counts for naïve effector and activated T cells were 423 424 calculated using the absolute frequencies of parent populations acquired from the BD TruCount 425 tubes. Cell phenotyping assays were validated and accredited in line with ISO15189 standards. 426 Classical, intermediate and non-classical monocytes were characterised by CD14 and CD16 expression. The maturation status of CD16+ neutrophils was evaluated by CD10 expression. 427 428 Antibodies used in flow cytometry phenotyping are in **Supplemental Table 1**. The reference 429 ranges for all assays were generated using a panel of 40 healthy controls and were established in a pre-pandemic setting. 430

#### 431 Physical Health Assessment

Physical health assessment occurred at time of outpatient assessment and convalescent immunophenotyping. Patients were asked a binary question as to whether or not they felt back to full health. Fatigue was assessed using the Chalder Fatigue Scale (CFQ-11) (47, 48). Participants answer eleven questions in relation to physical and psychological fatigue, with reference to the past month in comparison to their pre-COVID-19 baseline. A Likert scale (0-3) is used to measure responses, constructing a total score ranging from 0 to 33 (49).

The CFQ-11 also allows differentiation of "cases" vs "non-cases" where scores 0 and 1 (*Better than usual/No worse than usual*) are scored a zero and scores 2 and 3 (*Worse than usual/Much worse than usual*) are scored a 1 (bimodal scoring). Those with a total score of four or greater are

441 considered to meet the criteria for fatigue. This latter method for *caseness* resembles other442 fatigue questionnaires (49-52).

To assess cardiopulmonary and musculoskeletal function, a 6MWT was used, with total distance covered recorded (53, 54). The MBS, widely used in both healthy and diseased states to analyse exertion during submaximal exercise, assessed perceived exertion during the 6MWT (range 0 -10) (55, 56).

447 Statistical analysis

All statistical analysis was carried out using STATA v15.0 (Texas, USA) and statistical significance
considered p<0.05. Descriptive statistics are reported as means with standard deviations (SD)</li>
and median with interquartile ranges (IQR) as appropriate.

451 Between-group differences were assessed using t-tests, Wilcoxon rank-sum and chi-square tests 452 according to underlying data type and distribution. Paired analysis of laboratory parameters and 453 immune cell populations were carried out using Wilcoxon sign-rank test. Linear regression was used to model the relationship between immune cell parameters (independent variable) and 454 455 CFQ-11/6MWT (distance covered in metres) / MBS score using separate linear models. These 456 were performed unadjusted in the first instance (Model 1), followed by adjustment for age, sex, 457 and severity of initial infection (Model 2). Results are presented as  $\beta$  coefficients with 458 corresponding 95% confidence intervals (Cis) and p values. Correlation analysis between parameters was performed using Spearman correlation tests. 459

460 *Study approval* 

Ethical approval for the current study was obtained from the Tallaght University Hospital
(TUH)/St James's Hospital (SJH) Joint Research Ethics Committee (reference REC 2020-03).
Informed consent was obtained from all participants in the current study in accordance with the
Declaration of Helsinki (57).

#### 465 Author contributions

Conceptualisation: LT, AHD, COF, CNC, NMB and C.N.C.; Methodology: LT, AHD, AN, RK, DH, MG,
JDo, KOB, PF, NMB and NC. Formal Analysis: LT, AHD, JDu and NMB Investigation: LT, AN, RK, DH,
MG, JDo, KOB, CBa, PN, IML; Resources: JDu, IML, CBe, COF, CNC, NMB and NC.; Data Curation:
LT, AHD, AN, RK, JDu and NC; Writing-Original Draft: LT, AHD, CNC, NMB and NC; Writing-Review
& Editing: AN, JDu, IML, PF, CBe, COF, CNC, NMB and NC ; Visualisation: LT, AHD, AN, RK, DH, MG
and NMB; Supervision: IML, CBe, COF, CNC, NMB and NC; Funding Acquisition: LT and NC

#### 472 Acknowledgements

We would like to thank all patients involved in the study, the support provided by the Clinical
Research Facility at Saint James's Hospital, the STAR-Bioresource team, as well as the work of the
clinicians and multi-disciplinary team in the outpatient clinic.

#### 476 Funding

LT has been awarded the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland (https://icatprogramme.org/). NC is partfunded by a Science Foundation Ireland (SFI) grant, Grant Code 20/SPP/3685. The funders had

- 482 no role in study design, data collection and analysis, decision to publish, or preparation of the
- 483 manuscript.

## 484 **Competing Interests**

485 The authors have no competing interests to declare.

## **References**

488	1.	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult
489		inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020.
490	2.	Kerr C, Hughes G, Mckenna L, and Bergin C. Prevalence of smell and taste dysfunction in a
491		cohort of CoVID19 outpatients managed through remote consultation from a large urban
492		teaching hospital in Dublin, Ireland. Infection Prevention in Practice. 2020:100076.
493	3.	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics
494		of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The
495		Lancet. 2020;395(10223):507-13.
496	4.	Mallapaty S. The coronavirus is most deadly if you are older and male-new data reveal the risks.
497		Nature. 2020:16-7.
498	5.	Mahase E. British Medical Journal Publishing Group; 2020.
499	6.	Zhou Y, Fu B, Zheng X, Wang D, and Zhao C. Pathogenic T cells and inflammatory monocytes
500		incite inflammatory storm in severe COVID-19 patients. National Science Review. 2020.
501	7.	Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, et al. COVID-19
502		Coagulopathy in Caucasian patients. British Journal of Haematology. 2020.
503	8.	Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, et al. Severe COVID-
504		19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182(6):1419-40. e23.
505	9.	Carissimo G, Xu W, Kwok I, Abdad MY, Chan Y-H, Fong S-W, et al. Whole blood
506		immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for
507		severe COVID-19. Nature Communications. 2020;11(1):1-12.
508	10.	Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et
509		al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell host
510		& microbe. 2020.
511	11.	Laing AG, Lorenc A, Del Barrio IDM, Das A, Fish M, Monin L, et al. A dynamic COVID-19 immune
512		signature includes associations with poor prognosis. Nature medicine. 2020;26(10):1623-35.
513	12.	Greenhalgh T, Knight M, A'Court C, Buxton M, and Husain L. Management of post-acute covid-
514		19 in primary care. BMJ. 2020;370:m3026.
515	13.	Files JK, Boppana S, Perez MD, Sarkar S, Lowman KE, Qin K, et al. Sustained cellular immune
516		dysregulation in individuals recovering from SARS-CoV-2 infection. The Journal of Clinical
517		Investigation. 2020.
518	14.	Assaf G, Davis H, McCorkell L, Wei H, O'Neill B, and Akrami A. What Does COVID-19 Recovery
519		Actually Look Like? An Analysis of the Prolonged COVID-19 Symptoms Survey by Patient-Led
520		Research Team. London, UK: The COVID-19 Body Politic Slack Group; 2020. Contract. 2020(2).
521	15.	Carfi A, Bernabei R, and Landi F. Persistent symptoms in patients after acute COVID-19. JAMA.
522		2020.
523	16.	COVID GA, and Group P-ACS. Post-COVID-19 global health strategies: the need for an
524		interdisciplinary approach. Aging Clinical and Experimental Research.1.
525	17.	Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al. One-
526		year outcomes in survivors of the acute respiratory distress syndrome. New England Journal of
527		Medicine. 2003;348(8):683-93.
528	18.	Enright PL, and Sherrill DL. Reference equations for the six-minute walk in healthy adults.
529		American journal of respiratory and critical care medicine. 1998;158(5):1384-7.
530	19.	Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, et al. T-cell exhaustion in chronic
531		infections: reversing the state of exhaustion and reinvigorating optimal protective immune
532		responses. Frontiers in immunology. 2018;9:2569.

533	20.	Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, Broliden K, et al. Prolonged activation of
534		virus-specific CD8+ T cells after acute B19 infection. <i>PLoS Med</i> . 2005;2(12):e343.
535	21.	Zhao M, Chen J, Tan S, Dong T, Jiang H, Zheng J, et al. Prolonged evolution of virus-specific
536		memory T cell immunity after severe avian influenza A (H7N9) virus infection. Journal of
537		virology. 2018;92(17).
538	22.	Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. 'Long-COVID': a cross-
539		sectional study of persisting symptoms, biomarker and imaging abnormalities following
540		hospitalisation for COVID-19. Thorax. 2020.
541	23.	Gavriilaki E, Anyfanti P, Gavriilaki M, Lazaridis A, Douma S, and Gkaliagkousi E. Endothelial
542		Dysfunction in COVID-19: Lessons Learned from Coronaviruses. Current hypertension reports.
543		2020;22(9):1-12.
544	24.	Thachil J. All those D-dimers in COVID-19. Journal of Thrombosis and Haemostasis. 2020.
545	25.	Hurley A, Smith M, Karpova T, Hasley RB, Belkina N, Shaw S, et al. Enhanced effector function of
546		CD8+ T cells from healthy controls and HIV-infected patients occurs through thrombin activation
547		of protease-activated receptor 1. The Journal of infectious diseases. 2013;207(4):638-50.
548	26.	Kasahara TM, Hygino J, Andrade RM, Monteiro C, Sacramento PM, Andrade AF, et al. Poor
549		functional immune recovery in aged HIV-1-infected patients following successfully treatment
550		with antiretroviral therapy. Human Immunology. 2015;76(10):701-10.
551	27.	Chen J, Kelley WJ, and Goldstein DR. Role of Aging and the Immune Response to Respiratory
552		Viral Infections: Potential Implications for COVID-19. The Journal of Immunology. 2020.
553	28.	Sun J, and Braciale TJ. Role of T cell immunity in recovery from influenza virus infection. <i>Current</i>
554		opinion in virology. 2013;3(4):425-9.
555	29.	Leng J, and Goldstein DR. Impact of aging on viral infections. Microbes and infection.
556		2010;12(14-15):1120-4.
557	30.	Woodland DL, and Blackman MA. Immunity and age: living in the past? Trends in immunology.
558		2006;27(7):303-7.
559	31.	Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, et al. Viral epitope profiling of COVID-19
560		patients reveals cross-reactivity and correlates of severity. Science. 2020.
561	32.	Crooke SN, Ovsyannikova IG, Poland GA, and Kennedy RB. Immunosenescence and human
562		vaccine immune responses. Immunity & Ageing. 2019;16(1):25.
563	33.	Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, and Sztein MB.
564		Vaccination in the elderly: an immunological perspective. Trends in immunology.
565		2009;30(7):351-9.
566	34.	Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following
567		SARS-CoV-2 infection is common and independent of severity of initial infection. Plos one.
568		2020;15(11):e0240784.
569	35.	Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, et al. Symptom duration and risk
570		factors for delayed return to usual health among outpatients with COVID-19 in a multistate
571		health care systems network—United States, March–June 2020. Morbidity and Mortality Weekly
572		Report. 2020;69(30):993.
573	36.	Kim J, Chang D-Y, Lee HW, Lee H, Kim JH, Sung PS, et al. Innate-like cytotoxic function of
574		bystander-activated CD8+ T cells is associated with liver injury in acute hepatitis A. Immunity.
575		2018;48(1):161-73. e5.
576	37.	Sandalova E, Laccabue D, Boni C, Tan AT, Fink K, Ooi EE, et al. Contribution of herpesvirus
577		specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog. 2010;6(8):e1001051.
578	38.	Graham AL, Allen JE, and Read AF. Evolutionary causes and consequences of immunopathology.
579		Annu Rev Ecol Evol Syst. 2005;36:373-97.

580	39.	Münz C, Lünemann JD, Getts MT, and Miller SD. Antiviral immune responses: triggers of or
581		triggered by autoimmunity? Nature Reviews Immunology. 2009;9(4):246-58.
582	40.	van Aalst S, Ludwig IS, van der Zee R, van Eden W, and Broere F. Bystander activation of
583		irrelevant CD4+ T cells following antigen-specific vaccination occurs in the presence and absence
584		of adjuvant. PLoS One. 2017;12(5):e0177365.
585	41.	Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory
586		syndrome in children: A systematic review. <i>EClinicalMedicine</i> . 2020;26:100527.
587	42.	Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem
588		inflammatory syndrome in children and adolescents. The Lancet Infectious Diseases. 2020.
589	43.	Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, et al. Mapping systemic
590		inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-
591		C). <i>Cell</i> . 2020.
592	44.	Menikou S, Langford PR, and Levin M. Kawasaki disease: the role of immune complexes
593		revisited. Frontiers in immunology. 2019;10:1156.
594	45.	Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in
595		serum from patients hospitalized with COVID-19. Science Translational Medicine. 2020.
596	46.	Vella LA, Giles JR, Baxter AE, Oldridge DA, Diorio C, Kuri-Cervantes L, et al. Deep Immune
597		Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and
598		pediatric COVID-19. <i>medRxiv</i> . 2020.
599	47.	Butler S, Chalder T, Ron M, and Wessely S. Cognitive behaviour therapy in chronic fatigue
600		syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 1991;54(2):153-8.
601	48.	Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a
602		fatigue scale. Journal of psychosomatic research. 1993;37(2):147-53.
603	49.	Jackson C. The Chalder fatigue scale (CFQ 11). Occupational Medicine. 2015;65(1):86
604	50.	Morriss R, Wearden A, and Mullis R. Exploring the validity of the Chalder Fatigue scale in chronic
605		fatigue syndrome. Journal of psychosomatic research. 1998;45(5):411-7.
606	51.	Loge JH, Ekeberg ${\it {m \emptyset}}$ , and Kaasa S. Fatigue in the general Norwegian population: normative data
607		and associations. Journal of psychosomatic research. 1998;45(1):53-65.
608	52.	Jackson C. The general health questionnaire. Occupational medicine. 2007;57(1):79
609	53.	Weisman IM, and Zeballos RJ. Clinical exercise testing. Clinics in chest medicine. 2001;22(4):679-
610		701.
611	54.	Laboratories ACoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit
612		<i>Care Med.</i> 2002;166:111-7.
613	55.	Borg E, Borg G, Larsson K, Letzter M, and Sundblad BM. An index for breathlessness and leg
614		fatigue. Scandinavian journal of medicine & science in sports. 2010;20(4):644-50.
615	56.	Bausewein C, Farquhar M, Booth S, Gysels M, and Higginson I. Measurement of breathlessness
616		in advanced disease: a systematic review. Respiratory medicine. 2007;101(3):399-410.
617	57.	Association WM. World Medical Association Declaration of Helsinki. Ethical principles for
618		medical research involving human subjects. Bulletin of the World Health Organization.
619		2001;79(4):373.
630		
620		

## 622 Figure 1

#### A. Coagulopathy



623



625 (A) Coagulopathy (fibrinogen, D-dimer) (B) Inflammatory (CRP, IL-6, sCD25, IL-1β, IL-8, TNFα,

626 LDH) (C) Cell turnover (lymphocytes, neutrophil: lymphocyte ratio, neutrophils). Shaded areas

627 show normal ranges for each measure. Differences assessed by Wilcoxon signed-rank test. \* p

628 <0.05, \*\* p <0.01, \*\*\*p<0.001, NS = Not Significant



630

Figure 2: Myeloid populations from acute to convalescent COVID-19. Matched peripheral whole
 blood myeloid cell proportions from n=40 patients recovered from COVID-19 versus uninfected
 controls (n=20). (A) CD10-CD16- immature neutrophils (B) CD10+ neutrophils (C) HLA-DR+
 monocytes (D) non-classical monocytes (E) intermediate monocytes (F) classical monocytes.
 Differences assessed using Wilcoxon rank-sum (unpaired) and Wilcoxon sign-rank (paired) tests.

636 \* p <0.05, \*\* p <0.01, \*\*\*p<0.001, NS = Not Significant

637 Figure 3



Figure 3: Lymphocyte subsets from acute to convalescent COVID-19. Matched peripheral whole
blood lymphoid cell counts from n=40 patients recovered from COVID-19 versus uninfected
controls (n=40). (A) CD45+ immune cells (B) CD3+ lymphocytes (C) CD4+ T cells (D) CD8+ T cells
(E) naïve CD4+ T cells (F) naïve CD8+ T cells (G) effector CD8+ T cells (H) activated CD4+ T cells (I)
activated CD8+ T cells. Differences assessed using Wilcoxon rank-sum (unpaired) and Wilcoxon
sign-rank (paired) tests. \* p <0.05, \*\* p <0.01, \*\*\*p<0.001, NS = Not Significant</li>





- Figure 4: Lymphocyte subsets in convalescent COVID-19. Convalescent lymphocyte subsets from 649 n=71 patients recovered from COVID-19 versus n=40 uninfected controls. (A) CD4+ T cells,
- 650
- showing proportion and absolute number of naïve and activated CD4+ T cells (B) CD8+ T cells, 651 showing proportion and absolute number of naïve, activated and effector CD8+ T cells, Wilcoxon 652
- rank-sum test used to assess differences. \* p <0.05, \*\* p <0.01, \*\*\*p<0.001, NS = Not Significant 653

654 Figure 5



655

**Figure 5**: Relationship between D-dimers and lymphocyte subsets in convalescent COVID-19.

657 Correlation between D-dimers and (A) naïve CD8+ T cells, (B) activated CD4+ T cells and (C)

658 activated CD8+ lymphocytes. D-dimer shown as log scale. Dashed vertical line represents lower

659 limit of detection for D-dimer assay. Correlation assessed by Pearson's chi-squared test.



Figure 6: Age-associated changes in convalescent lymphocyte subsets versus age-matched
controls. Lymphocyte immunophenotyping of convalescent COVID patients (n=111) broken
down by age with age-matched controls, showing absolute number of (A) naïve CD4+ T cells and
(B) activated CD4+ T cells, and (C) naïve CD8+ T cells, (D) activated CD8+ T cells and (E) effector
CD8+ T cells. Differences assessed by Wilcoxon rank-sum test. \* p <0.05, \*\* p <0.01, \*\*\*p<0.001,</li>
NS = Not Significant

#### 670 Figure 7

A. Naive CD4+ T cells



Figure 7: Relationships of lymphocyte subsets with physical health measures and D-dimers.
Relationship with fatigue, perceived exertion and 6MWT distance with (A) naïve CD4+ T cells, (B)
naïve CD8+ T cells, (C) effector CD8+ T cells, (D) activated CD4+ T cells and (E) activated CD8+ T
cells. Relationships assessed using linear regression. CFQ-11 = Chalder Fatigue Questionnaire-11

## 677 Table 1: Cohort characteristics

Characteristic	AII (n = 111)	Cohort One (n = 40)	Cohort Two (N = 71)	Statistic
		(11 – 40)	(14 - 71)	
Sex, female, n (%)	70 (63.06)	21 (52.5)	49 (70)	χ <sup>2</sup> = 8.3, p = 0.004
Age, mean (SD)	45.9 (14.9)	51.4 (16.9)	44.3 (14.1)	t = 2.2, p = 0.01
Clinical Frailty Score, median (IQR)	1 (1 – 2)	2 (1 – 2.5)	1 (1-2)	z = -4.3, p <0.001
Co-morbidities, median, n (IQR)	1 (0 – 2)	1 (0 – 2)	0 (0-2)	z = -1.11, p = 0.27
Co-medications, median, n (IQR)	1 (0 – 3)	1 (0 – 4)	1 (0-2)	z = -1.14, p = 0.25
Admission during acute infection, n (%)	48 (43)	30 (75)	18 (25)	χ <sup>2</sup> = 25.7, p <0.001
Admission to ICU, n (%)	14 (12.6)	8 (20)	6 (8)	$\chi^2 = 3.1, p = 0.08$
Time to follow up, days, median (IQR)	82 (67 – 112)	68 (60.5 – 71)	101 (76-117)	z = 5.04, p <0.001
Feel back to full health (yes), n (%)	37 (33)	22 (55)	15 (21.2)	χ <sup>2</sup> = 16.7, p <0.001
Healthcare worker, n (%)	74 (66.7)	15 (37.5)	59 (83)	χ <sup>2</sup> = 23.9, p <0.001
Distance at 6MWT, m, median (IQR)	475 (415 – 540)	435 (390 – 540)	480 (430-540)	z = 4.5, p = 0.65
MBS, median (IQR)	3 (2 – 5)	3 (2 – 5)	3 (2 - 5)	z = -0.42, p = 0.68
Fatigue score, median (IQR)	15 (11 – 20)	13 (11 – 18)	17 (12 - 21)	z = 1.58, p = 0.11
Fatigue <i>caseness</i> , n (%)	61 (55)	15 (37.5)	46 (65)	χ <sup>2</sup> = 7.7, p 0.01

678

 $\chi^2$ , Chi-squared test; t, t-test; z, Wilcoxon rank-sum test.6MWT, 6-minute-walk test; MBS, Modified Borg Dyspnoea Scale

## 680 Table 2. Active COVID-19 is associated with a significant pro-inflammatory response which normalises following resolution of

## 681 acute infection

Laboratory Parameter	Reference Range	Values		Statistic	N (%) Abnormal Results	
		Acute COVID-19	Post COVID-19		Acute COVID-19	Post COVID- 19
Routine Laboratory Markers						
Neutrophil Count (x10 <sup>9</sup> /L)	2-7.5	3.5 (2.3-4.4)	3.15 (2.55-4.05)	z =0.47, p =0.64	5 (13%)	0 (0%)
Lymphocyte Count (x10 <sup>9</sup> /L)	1.5-3.5	1.3 (1-1.8)	1.9 (1.55-2.35)	z=-2.85, p = 0.004	24 (60%)	5 (13%)
Neutrophil: Lymphocyte		2.5 (1.3-3.9)	1.7 (1.3-2.1)	z =2.82, p = 0.005		
Lactate Dehydrogenase (U/L)	135-250	230 (190-308)	187.5 (165-210)	z = 3.27, p = 0.001	14 (35%)	0 (0%)
Fibrinogen (g/L)	1.9-3.5	4.4 (3.6-6)	3 (2.6-3.4)	z = 2.86, p = 0.004	22 (55%)	2 (5%)
D-Dimer (ng/mL)	0-500	496 (258-851)	396 (215-599)	z = 1.93, p = 0.05	20 (50%)	10 (25%)
C Reactive Protein (mg/L)	0-5	28.15 (3.16-53.58)	1.43 (1.00-1.99)	z = 4.75, p<0.001	31 (78%)	3 (8%)
Pro-Inflammatory Cytokines						
IL-6 (pg/mL)		15.3 (4.19-31.7)	2.17 (1.45-3.35)	z = 4.72, p<0.001	22 (55%)	3 (8%)
IL-1β		0.26 (0.18-0.45)	0.19 (0.11-0.31)	z = 2,1, p = 0.035	1 (2.5%)	1 (2.5%)
ΤΝFα		21.3 (16-25)	12.2 (10.3-14.8)	z = 3.95, p<0.001	16 (40%)	2 (5%)
IL-8		31.1 (20.3-46.4)	16.5 (12.3-21.4)	z = 4.23, p<0.001	17 (42.5%)	4 (10%)
Soluble CD25 (pg/mL)		1,898 (1520-2455)	1,187 (878-1634)	z = 4.61, p<0.001	11 (28%)	2 (5%)

682

Data presented as medians with IQRs. z, Wilcoxon matched pair

# Table 3: No relationship between extended T cell subsets and symptoms of fatigue, dyspnoea or distance walked on the six minute walk test post-COVID-19.

	CFQ-11				6MWT (meters)				Borg Dyspnoea Scale			
	Model 1		Model 2 (adj.)		Model 1		Model 2 (adj.)		Model 1		Model 2 (adj.)	
	β Coeff (95% Cl)	Р	Adj. β Coeff (95% Cl)	р	β Coeff (95% Cl)	р	Adj. β Coeff (95% Cl)	р	β Coeff (95% Cl)	р	Adj. β Coeff (95% Cl)	р
Naïve CD4 Count	0.005 (0.00, 0.01)	0.046	0.004 (-0.001, 0.01)	0.07	-0.05 (-0.19, 0.09)	0.50	-0.14 (-0.26, -0.02)	0.02	-0.0002 (-0.003, 0.002)	0.83	-0.0002 (-0.003, 0.002)	0.89
Naïve CD8 Count	0.01 (0.001, 0.02)	0.04	0.01 (0.001, 0.02)	0.04	0.20 (-0.03, 0.42)	0.08	-0.10 (-0.34, 0.13)	0.39	0.001 (-0.003, 0.005)	0.70	0.003 (-0.002, 0.008)	0.21
Effector CD8 Count	-0.002 (-0.01, 0.01)	0.63	0.003 (-0.05, 0.05)	0.92	-0.04 (-0.20, 0.12)	0.65	0.01 (-0.13, 0.15)	0.85	-0.002 (-0.005, 0.001)	0.22	-0.002 (-0.004, 0.001)	0.23
Activated CD4 Count	0.04 (-0.69, 0.77)	0.82	-0.01 (-0.06, 0.04)	0.75	-1.04 (-2.31, 0.23)	0.11	-0.0002 (-1.19, 1.19)	0.99	-0.0001 (-0.02, 0.02)	0.99	-0.01 (-0.03, 0.02)	0.48
Activated CD8 Count	-0.01 (-0.02, 0.01)	0.32	-0.01 (-0.02, 0.004)	0.20	-0.08 (-0.35, 0.19)	0.56	0.09 (-0.16, 0.33)	0.48	-0.003 (-0.008, 0.002)	0.23	-0.004 (-0.01, 0.001)	0.10

686

Linear regression. CI; confidence interval. Model 1, unadjusted; Model 2, adjusted for age, sex, Clinical Frailty Scale and severity of

acute COVID-19 illness. Bonferroni correction, statistical significance p <0.01



### Supplemental Figure 1: Patient enrolment diagram

## Supplemental Figure 2: Recovery of B and NK cells



**Supplemental Figure 2:** Matched peripheral whole blood lymphoid cell counts from n=40 patients recovered from COVID-19 versus uninfected controls (n=40). **(A)** B cells **(B)** NK cells. Wilcoxon rank-sum (unpaired) and Wilcoxon sign-rank (paired) tests.\* p <0.05, \*\* p <0.01, ns = Not Significant

## Supplemental Figure 3: Major lymphoid populations in convalescent COVID-19.



**Supplemental Figure 3:** Major lymphoid populations in n=71 convalescent COVID patients in comparison to n=40 controls (A) CD45+ cells (B) CD3+ lymphocytes (C) CD4+ T cells (D) CD8+ T cells. Wilcoxon rank-sum test ns=not significant





**Supplemental Figure 4:** Monocyte subpopulations in n=71 convalescent COVID patients in comparison to n=20 controls (A) nonclassical monocytes (B) intermediate monocytes (C) classical monocytes. Wilcoxon rank-sum test. ns=not significant



Supplemental Figure 5: Age-associated changes in convalescent lymphocyte subsets

**Supplemental Figure 5:** Lymphocyte immunophenotyping of convalescent COVID patients (n=111) broken down by age. (A) naïve CD4+ T cell count (B) naïve CD8+ T cell count (C) effector CD8+ T cell count (D) activated CD4+ T cell count (E) activated CD8+ T cell count (F) naïve CD4+ T cell proportion (G) naïve CD8+ T cell proportion (H) effector CD8+ T cell proportion (I) activated CD4+ T cell proportion (J) activated CD8+ T cell proportion. Kruskal-Wallis test with post-hoc Dunn test.\* p <0.05, \*\* p <0.01, \*\*\*p<0.001, ns = Not Significant

# Supplemental Figure 6: Age-associated changes in convalescent lymphocyte subset proportions versus age-matched controls



**Supplemental Figure 6:** Lymphocyte immunophenotyping of convalescent COVID patients (n=111) broken down by age with age-matched controls, sowing proportions of naïve (A) and activated (B) CD4+ T cells, and naïve (C), activated (D) and effector (E) CD8+ T cells. Differences assessed by Kruskal-Wallis test with post-hoc Dunn test.\* p <0.05, \*\* p <0.01, \*\*\*p<0.001, NS = Not Significant



#### Supplemental Figure 7: Relationships of monocyte subsets with physical health measures

p = 0.22 p = 0.63 100-p = 0.58 Classical monocytes (%) Classical monocytes (%) Classical monocytes (%)  $r^2 = -0.14$ = 0.05  $r^2 = 0.07$ 50-ò 200 300 400 500 CFQ-11 Borg Dyspnoea Scale (Max) 6 Minute Walk Test (m)

**Supplemental Figure 7:** Relationship with fatigue, perceived exertion and 6MWT distance in n=101 convalescent COVID patients with (A) non-classical monocytes (B) intermediate monocytes (C) classical monocytes. Correlation assessed with Pearson's chi-squared test. CFQ-11 = Chalder Fatigue Questionnaire-11



## Supplemental Figure 8: Flow cytometry gating strategy.

**Supplemental Figure 8:** Gating strategy for flow cytometry shown **(A)** naïve and effector T lymphocytes **(B)** activated T lymphocytes **(C)** neutrophils **(D)** monocytes

# Supplemental Table 1: Flow cytometry antibodies

Antibody	Fluorophore	Clone	Company	Catalogue #
CD45	V500-C	2D1	BD Biosciences	655873
CD8	V450	RPA-T8	BD Biosciences	560347
CD3	APC-H7	SK7	BD Biosciences	641415
CD4	PerCP/CY5.5	Sk3	BD Biosciences	332772
CD45RA	PE	-	BD Biosciences	556627
CD27	FITC	-	BD Biosciences	555440
CD197	Alexa Fluor 647	150503	BD Biosciences	560816
HLA DR	FITC	L243	BD Biosciences	347400
CD38	АРС	НВ-7	BD Biosciences	345807
CD14	АРС	МФР9	BD Biosciences	345787
CD16	PE	B73.1	BD Biosciences	332779
CD10	АРС	HI10a	BD Biosciences	332777